Praxis Precision Medicines, INC Form 4 insider transactions

Alex Nemiroff, General Counsel and Secretary of Praxis Precision Medicines, reports acquisition of restricted stock units and stock options, as well as disposal of common stock.

Lauren Mastrocola, Principal Accounting Officer at Praxis Precision Medicines, received 4,500 restricted stock units and options to purchase 21,000 shares of common stock on July 29, 2024.

Chief Financial Officer Timothy Edwin Kelly of Praxis Precision Medicines reports the acquisition of restricted stock units and stock options.

Director Jill DeSimone acquired stock options in Praxis Precision Medicines, Inc. on June 5, 2024.

Director Dean J. Mitchell acquired stock options for 8,566 shares of Praxis Precision Medicines, Inc. on June 5, 2024.

Director Jeffrey Chodakewitz acquired stock options in Praxis Precision Medicines, Inc. on June 5, 2024.

Merit Ester Cudkowicz, a director at Praxis Precision Medicines, acquired stock options exercisable for 8,566 shares of common stock on June 5, 2024.

Director William Young acquired stock options for 8,566 shares of Praxis Precision Medicines, Inc. on June 5, 2024.

Gregory Norden, a director at Praxis Precision Medicines, acquired stock options for 8,566 shares on June 5, 2024.

Timothy Edwin Kelly, CFO of Praxis Precision Medicines, reports acquiring 606 shares of common stock through the company's Employee Stock Purchase Plan.

Praxis Precision Medicines CEO Marcio Souza acquired 1,718 shares of common stock through the company's Employee Stock Purchase Plan at a price of $12.368 per share.